- Home
- Results news
- Bacil Pharma
- Q2 FY27 results
Bacil Pharma Q2 FY27 results: net profit ₹0.09 crore
Bacil Pharma Ltd reported ₹0 crore of consolidated revenue in Q2 FY27, alongside a net profit of ₹0.09 crore and basic EPS of ₹0.06. The results were announced on 14 October 2026, and the stock’s reaction-day close was 4.7% below its pre-results close.
Key points
- Consolidated Q2 FY27 revenue was ₹0 crore, while other income was ₹0.09 crore.
- Consolidated net profit was ₹0.09 crore and basic EPS was ₹0.06.
- The standalone quarter showed other income of ₹0.09 crore, total expenses of ₹0.12 crore and profit before tax of ₹0.03 crore.
- Consolidated total assets were ₹30.81 crore and total equity was ₹25.22 crore as of 30 September 2026.
- The stock closed 4.7% lower on the reaction day and 13.1% lower by the fifth session from its pre-results close.
How did Bacil Pharma perform in Q2 FY27?
Bacil Pharma reported consolidated revenue of ₹0 crore in the quarter ended 30 September 2026. Other income was ₹0.09 crore and total expenses were ₹0.12 crore. The company reported a net profit of ₹0.09 crore and basic EPS of ₹0.06 for Q2 FY27, with no exceptional item.
The standalone filing reported total revenue of ₹0.09 crore for the quarter and ₹0.18 crore for the first half. Quarter-end standalone basic EPS was ₹0.03. The filing did not provide consolidated figures for the year-ago quarter or the previous quarter, so comparisons with those periods are not available.
| ₹ crore | Q2 FY27 |
|---|---|
| Revenue from operations | 0 |
| Other income | 0.09 |
| Total expenses | 0.12 |
| EBITDA | −0.06 |
| Profit before tax | −0.03 |
| Tax | 0.04 |
| Net profit | 0.09 |
| EPS (₹) | 0.06 |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
As of 30 September 2026, the consolidated balance sheet showed total assets of ₹30.81 crore, total equity of ₹25.22 crore, borrowings of ₹0 crore and cash of ₹0.97 crore. Trade receivables were ₹1.11 crore. A comparison with the previous balance-sheet date was not provided.
For H1 FY27, consolidated cash flow from operating activities was ₹1.59 crore of outflow, while investing activities generated ₹1.62 crore and financing activities generated ₹0.37 crore. A year-earlier cash-flow comparison was not provided.
| ₹ crore | As of 30 September 2026 |
|---|---|
| Total assets | 30.81 |
| Total equity | 25.22 |
| Borrowings | 0 |
| Cash and equivalents | 0.97 |
| Inventories | 0 |
| Trade receivables | 1.11 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 |
|---|---|
| Cash from operations | −1.59 |
| Cash from investing | 1.62 |
| Cash from financing | 0.37 |
| Capital expenditure | 0 |
Source: Company's results filing (XBRL).
How did Bacil Pharma shares react?
The filing appeared after market hours. Bacil Pharma was down 2.0% after five minutes and 2.8% after 15 minutes; it was unchanged after 30 minutes. On the reaction day, the stock closed 4.7% below its pre-results close of ₹23.00.
By the next day’s close, the stock was down 6.9% from its pre-results close, and by the fifth session it was down 13.1%. The Pharmaceuticals industry median moved 0.6% lower on the reaction day, 0.7% lower by the next day and 6.0% lower by the fifth session, leaving Bacil Pharma behind by 4.1 percentage points, 6.2 percentage points and 7.1 percentage points.
| After the filing | Stock | Pharmaceuticals median |
|---|---|---|
| 5 minutes | −2.0% | |
| 15 minutes | −2.8% | |
| 30 minutes | +0.0% | |
| Reaction day | −4.7% | −0.6% |
| Next day | −6.9% | −0.7% |
| 5 days | −13.1% | −6.0% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
| Results filed on | Stock on the reaction day |
|---|---|
| 12 August 2026 | −5.0% |
| 22 May 2026 | +0.1% |
| 13 February 2026 | −6.6% |
| 13 November 2025 | +4.9% |
| 23 October 2024 | +2.0% |
| 14 August 2024 | −1.6% |
| 21 May 2024 | −2.0% |
Source: MarketPing price-reaction measurement.
How did other Pharmaceuticals companies do?
A total of 61 other Pharmaceuticals companies were compared. Their median revenue growth was 18.9%. The available peer data did not state how many peers grew slower or faster than Bacil Pharma, so the required peer-growth counts could not be reported.
Profit growth was available for 55 peers, of which 39 reported higher profit. The comparison was recorded as of 4 November 2026.
| Bacil Pharma revenue growth (YoY) | not comparable |
|---|---|
| Median of 61 other Pharmaceuticals companies | +18.9% |
| Companies whose net profit rose | 39 of 55 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Bacil Pharma's revenue in Q2 FY27?
Revenue from operations was ₹0 crore (consolidated).
Did Bacil Pharma make a profit in Q2 FY27?
Yes. Net profit was ₹0.09 crore.
What was Bacil Pharma's EPS in Q2 FY27?
Basic earnings per share were ₹0.06.
How did Bacil Pharma shares react to the Q2 FY27 results?
On the reaction day the stock moved −4.7% from the previous close; the median Pharmaceuticals stock moved −0.6%.
When did Bacil Pharma announce its Q2 FY27 results?
On 14 October 2026, in a filing to the BSE.
Sources
- Board Meeting Intimation for We Wish To Inform That The Meeting Of The Board Of Directors Of The Company Is Scheduled To Be Held On Wednesday, 14Th October, 2026 (BSE, 5 October 2026) · PDF
- Board Meeting Outcome for Outcome Of Board Meeting Held On 14Th October, 2026 (BSE, 14 October 2026) · PDF
- Un-Audited Financial Result For The Quarter And Half Yearly Ended 30Th September, 2026 (BSE, 14 October 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.